Aegirbio has, together with NowMed Sweden, received a first order worth more than MSEK 400 for delivery to Asia. This is a result of the test order that was won in early June and will be supplied as soon as possible. The delivery is intended for Cambodia, Thailand, Laos, Vietnam and Singapore.
The need for simple and safe tests to control the spread of infection in countries where the vaccination rollout is less well advanced than for example in Europe is gigantic. In order to keep infrastructure, tourism, schools, and workplaces open, countries in the region are carrying out widespread testing efforts, and thus look for products that are easy to administer and provide reliable results. Aegirbio’s COVID-19 test has been selected for its simple test procedure, which allows it to be used for everything from small children at school to workplaces where it is important to conduct frequent sampling, and where nasal testing is unable to achieve sufficiently wide testing coverage.
"Our distributor in Asia has now demonstrated its success at promoting sales to the countries within the region. This is the final proof that Aegirbio is creating a strong market position in Asia. To receive an order of over MSEK 400, less than two years from the company’s inception, is a feat that I am extremely proud of. Alongside our partner NowMed Sweden, we will continue to work hard to consolidate our position even further, and we anticipate more orders in the fall,” says Martin Linde, CEO of Aegirbio.
This information is information that AegirBio is obliged to make public pursuant to the EU Market Abuse Regulation (Regulation (EU) No 596/2014). The information was submitted for publication, through the agency of the contact person set out above, at 09:05 CET on 2021-07-09.
For more information, please contact:
Anders Ingvarsson, SO Aegirbio AB
Telephone: +46 706 791 878
Martin Linde, CEO Aegirbio AB
Telephone: +46 706 730 968
Aegirbio is a Swedish diagnostics company established to offer tests to monitor and optimize the dosing of biological drugs by means of a unique, patented technology platform. Biological therapies is the fastest growing segment of the pharmaceutical industry; a quarter of all drugs are projected to be biological in 2020. At the same time, drug concentrations vary tremendously (up to 100 times) in patients that receive biological drugs in standard doses.
The result of this one size fits all-approach is that patients with low drug concentrations do not respond to treatment, while excessive drug concentrations increase the risk of adverse effects in others. The uncertainty surrounding dosing results in overdosing or underdosing in about 55 percent of the cases, which causes unnecessary costs, suboptimal clinical outcomes, and a higher proportion of patients suffering severe side effects.
The Company has completed acquisitions that ensure long-term access to key technologies and open up new application areas. Through these acquisitions, Aegirbio, rooted in laboratory testing, have in a short period of time added technologies and skills to the Company to make headway towards becoming the multidiagnostic company it has set out to be.
Aegirbio is now building its operations around technologies for
The acquisitions provide the Company the means to develop new diagnostics to enable people to monitor their own health issues. In addition to bringing innovative diagnostic technology to market, the Company’s ambition in that regard is to make diagnostics more accurate, easier to use and with precise and easily transferable results.
Certified adviser for the company is Eminova Fondkommission AB | +468-684 211 00 |email@example.com